WHITE PAPER

Inherited Retinal Diseases: Voice of the Patient

The vast majority of patients with inherited retinal diseases (IRDs) remain without disease-modifying treatment, despite the more than 30 therapeutic programs now in clinical development for IRDs.

This white paper combines insights from Genome Medical’s nationwide cohort of patients with IRD and peer-reviewed literature to highlight gaps and opportunities in IRD care with implications for clinical research, drug development, and patient access to emerging therapies.

The paper explores:

Download the paper below to explore:

• Diagnostic challenges and genetic testing gaps 
  
• The burden of IRD beyond visual acuity
• Patient interest in emerging gene therapies